# Textos enviados aos modelos (prompts exatos)

Condição neutra. Para cada cenário: contexto completo e trecho. A frase de procedência e o formato de resposta aparecem como foram enviados. O bloco SYSTEM é o mesmo em todos.

## SYSTEM (igual em todas as chamadas)

`
You are a methodologist reviewing a data-extraction table prepared for a systematic review and meta-analysis. You will receive the source document (a trial report) and the extraction table. Verify each cell against the source document and correct any errors. Reply only with JSON.
`

## freq-01 — gêmeo implausible — contexto completo

Alvos (nunca mostrados ao modelo): v1_af_regional=correct_implausible, verdade=0.02101; v1_reads=correct_plausible, verdade=96/97; v1_zygosity=wrong_plausible, verdade=homozygous; v1_vaf=wrong_implausible, verdade=0.9897

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01347
Date of report: 12 March 2026

PATIENT
Name: [redacted]  Sex: female  Age at sampling: 7 years 2 months
Referring physician: Pediatric genetics outpatient clinic
Specimen: peripheral blood (EDTA), proband, mother and father
Ordered test: trio exome sequencing with phenotype-driven analysis

CLINICAL INDICATION
The proband is a 7-year-old girl referred for progressive joint stiffness and corneal clouding. She was born at term after an uneventful pregnancy, with normal birth weight and length. Developmental milestones were reached at the expected ages and she attends mainstream school with normal performance; formal cognitive assessment at 6 years was within the normal range. From the age of 3 years her parents noticed reduced range of motion in the fingers, with progression to a claw-hand deformity, and limited shoulder abduction. Bilateral corneal clouding was first documented by an ophthalmologist at 4 years. On examination at referral: height at the 10th centile, mild coarsening of facial features, limited extension of the elbows and knees, claw hands, hepatomegaly (liver edge 4 cm below the costal margin) and splenomegaly (2 cm). Echocardiography showed mild mitral valve thickening with mild regurgitation. Hearing was normal on audiometry. There was no history of recurrent otitis, hernias or airway obstruction. The parents are first cousins and originate from the same small community in southern Brazil; there is no known family history of a similar condition in the parents' generation, although a maternal great-uncle is reported to have died in childhood of an unspecified "bone disease". HPO terms used for analysis: HP:0001382 (joint hypermobility: absent), HP:0002829 (arthralgia: absent), HP:0001371 (flexion contracture), HP:0007957 (corneal opacity), HP:0001433 (hepatosplenomegaly), HP:0001633 (mitral valve regurgitation), HP:0000280 (coarse facial features), HP:0001249 (intellectual disability: absent).

Biochemical results available at referral: quantitative urinary glycosaminoglycans 48.2 mg/mmol creatinine (age-specific reference < 10.6), with dermatan sulfate and heparan sulfate on electrophoresis. Alpha-L-iduronidase activity in leukocytes: 0.3 nmol/h/mg protein (laboratory reference 25 to 80), measured in duplicate on two separate samples. Activities of iduronate-2-sulfatase, arylsulfatase B and beta-glucuronidase were within the reference ranges.

RESULT SUMMARY
A homozygous missense variant in IDUA, NM_000203.5:c.1067A>G p.(His356Arg), classified as Pathogenic, was identified in the proband. Both parents are heterozygous carriers. This result, together with the biochemical findings, confirms a diagnosis of mucopolysaccharidosis type I (MPS I) of the attenuated (Hurler-Scheie) clinical form. In addition, a heterozygous variant of uncertain significance in GALNS was identified; it is not related to the proband's phenotype and is reported as a carrier finding. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANTS REPORTED

Variant 1 (primary finding)
Gene: IDUA (alpha-L-iduronidase), OMIM *252800; associated condition: mucopolysaccharidosis type I (OMIM #607014, #607015, #607016), autosomal recessive.
Transcript: NM_000203.5. Genomic position: chr4:g.1,002,363A>G (GRCh38).
cDNA: c.1067A>G. Protein: p.(His356Arg). Variant type: missense, exon 8.
Reads in proband: 96 of 97 reads supported the alternate allele at this position; the single reference read had base quality below 20.
Reads in mother: 54 of 110 reads supported the alternate allele.
Reads in father: 61 of 118 reads supported the alternate allele.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (homozygous) and in both parents (heterozygous).

Variant 2 (carrier finding, unrelated to phenotype)
Gene: GALNS (N-acetylgalactosamine-6-sulfatase), OMIM *612222; associated condition: mucopolysaccharidosis type IVA (OMIM #253000), autosomal recessive.
Transcript: NM_000512.5. Genomic position: chr16:g.88,837,650C>T (GRCh38).
cDNA: c.538G>A. Protein: p.(Val180Met). Variant type: missense, exon 5.
Zygosity in proband: heterozygous (47 of 92 reads, variant allele fraction 0.51). Inherited from the father (heterozygous); absent in the mother.
Population frequency: gnomAD v4.1 overall allele frequency 0.00004, no homozygotes.
Classification: Variant of uncertain significance (criteria: PM2_Supporting, PP3). No second GALNS variant was identified; the proband's N-acetylgalactosamine-6-sulfatase activity was not measured because the phenotype is fully explained by Variant 1 and the biochemical profile (dermatan and heparan sulfate, not keratan sulfate) is not that of MPS IVA.
Orthogonal confirmation: not performed (carrier finding).

INTERPRETATION

Variant 1: IDUA c.1067A>G p.(His356Arg)
This missense variant replaces a histidine by an arginine at codon 356, within the TIM-barrel catalytic domain of alpha-L-iduronidase. In silico predictors are concordant for a deleterious effect (REVEL 0.91; CADD 29.4; AlphaMissense: likely pathogenic). The variant is present in gnomAD v4.1 at an overall allele frequency of 0.00012 (12 per 100,000 alleles, no homozygotes). Its frequency in the proband's community of origin, from the regional carrier survey (Regional Rare Disease Registry, 2024), is addressed in the Discussion. Functional evidence: the proband's leukocyte alpha-L-iduronidase activity is 0.3 nmol/h/mg protein (reference 25 to 80), approximately 1% of the lower limit of normal, and expression of the p.(His356Arg) protein in a published cell-based assay yielded 2.4% of wild-type enzymatic activity, in the range reported for alleles associated with the attenuated phenotype. Applied criteria: PS3 (deficient alpha-L-iduronidase activity in patient leukocytes and in transfected cell lysates), PM3 (observed in trans with other pathogenic IDUA alleles in three unrelated affected individuals from the same region), PP1 (co-segregation with disease in the family), PP4 (phenotype and enzymatic profile highly specific for MPS I). BS1 was considered and not applied: the regional allele frequency reflects a founder effect, and the disease prevalence expected from it under Hardy-Weinberg equilibrium, approximately 1 in 2,300 births, is consistent with the number of MPS I cases ascertained in that community over the past two decades. The segregation pattern in the family is consistent with autosomal recessive inheritance.

Variant 2: GALNS c.538G>A p.(Val180Met)
This missense variant is rare in population databases and predicted deleterious by most in silico tools, but there is no functional or clinical evidence to support or refute a pathogenic effect. It was inherited from the father and is reported as a carrier finding only. MPS IVA is autosomal recessive and a single heterozygous variant does not cause disease.

CONFIRMATION AND SEGREGATION
Variant 1 was confirmed by bidirectional Sanger sequencing of IDUA exon 8 in the proband and both parents, using an independent DNA extraction from the same blood samples. The proband's electropherogram showed a single G peak at c.1067 (homozygous); each parent showed overlapping A and G peaks of similar height (heterozygous). Segregation is therefore consistent with autosomal recessive inheritance from heterozygous carrier parents. Relatedness analysis of the trio exome data confirmed the declared parental relationships and an inbreeding coefficient for the proband of 0.058, consistent with the reported first-cousin parental consanguinity.

DISCUSSION
The elevated frequency of the c.1067A>G allele in the proband's community of origin is explained by a founder effect. The community was settled in the nineteenth century by a small number of families and has remained geographically isolated. The regional survey genotyped 952 unrelated adults from the community (1,904 alleles) and identified 40 carrier alleles, all of which share a common 1.2-Mb haplotype around IDUA, consistent with descent from a single ancestral chromosome. Because the attenuated phenotype is compatible with survival to reproductive age, selection against the allele is weak, and the carrier frequency has been stable across the two surveyed generations. Homozygosity in the proband is therefore expected both from the parental consanguinity and from the regional enrichment of the allele.

The clinical picture (onset of joint contractures and corneal clouding in early childhood, hepatosplenomegaly, mild mitral valve disease, normal cognition at 7 years), the urinary glycosaminoglycan profile (dermatan and heparan sulfate) and the profound deficiency of alpha-L-iduronidase activity are each characteristic of MPS I, and together establish the diagnosis independently of the molecular result. The preserved cognition and the age at onset place the proband in the attenuated (Hurler-Scheie) end of the MPS I spectrum; genotype-phenotype correlation is imperfect in MPS I, and the clinical course should be followed rather than predicted from the genotype alone.

RECOMMENDATIONS
1. Referral to a metabolic disease centre for consideration of enzyme replacement therapy (laronidase) and for baseline assessment of cardiac, respiratory, skeletal, ophthalmological and audiological status.
2. Genetic counselling for the parents: recurrence risk of 25% in each future pregnancy; prenatal or preimplantation testing is available for the familial variant.
3. Cascade carrier testing for the familial IDUA variant may be offered to adult relatives on both sides of the family.
4. The GALNS variant of uncertain significance does not require clinical action. Carrier testing of the proband's future partner is not indicated on the basis of this finding alone; the classification will be revisited if new evidence becomes available.
5. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions, variants in regions of low coverage or high sequence homology, and mosaicism below approximately 15% variant allele fraction may not be detected. Population frequency data depend on the ancestries represented in the reference databases. Variant classification reflects the evidence available at the date of the report and may change. The reference ranges for enzymatic activity are laboratory-specific.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used. Mean target coverage in the proband was 102x, with 98.1% of target bases covered at 20x or more (mother: 97x, 97.8%; father: 104x, 98.3%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 62 genes associated with lysosomal storage disorders, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking IDUA exon 8. Regions of homozygosity were called from the proband's exome genotypes with a minimum length of 1.5 Mb.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory, registry and coordinates are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | female
patient_age | Age at sampling | 7 years 2 months
consanguinity | Parental consanguinity | yes (first cousins)
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 102
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.1
enzyme_activity | Alpha-L-iduronidase activity in leukocytes (nmol/h/mg protein) | 0.3
enzyme_reference | Alpha-L-iduronidase reference range (nmol/h/mg protein) | 25-80
urinary_gag | Urinary glycosaminoglycans (mg/mmol creatinine) | 48.2
urinary_gag_pattern | Urinary GAG electrophoresis pattern | dermatan sulfate and heparan sulfate
v1_gene | Variant 1: gene | IDUA
v1_transcript | Variant 1: transcript | NM_000203.5
v1_cdna | Variant 1: cDNA change (HGVS) | c.1067A>G
v1_protein | Variant 1: protein change (HGVS) | p.(His356Arg)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 8
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 96/97
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.40
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: zygosity in father | heterozygous
v1_gnomad_overall | Variant 1: gnomAD v4.1 allele frequency, overall | 0.00012
v1_af_regional | Variant 1: allele frequency in regional carrier survey (community of origin) | 0.021
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM3, PP1, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and both parents)
v1_inheritance | Variant 1: inheritance | autosomal recessive, biparental
v2_gene | Variant 2: gene | GALNS
v2_transcript | Variant 2: transcript | NM_000512.5
v2_cdna | Variant 2: cDNA change (HGVS) | c.538G>A
v2_protein | Variant 2: protein change (HGVS) | p.(Val180Met)
v2_zygosity | Variant 2: zygosity in proband | heterozygous
v2_origin | Variant 2: parental origin | paternal
v2_gnomad_overall | Variant 2: gnomAD v4.1 allele frequency, overall | 0.00004
v2_acmg | Variant 2: ACMG classification | VUS
v2_relevance | Variant 2: relevance to phenotype | unrelated; carrier finding
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | MPS I, attenuated (Hurler-Scheie)

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## freq-01 — gêmeo plausible — contexto completo

Alvos (nunca mostrados ao modelo): v1_af_regional=correct_plausible, verdade=0.000525; v1_reads=correct_plausible, verdade=96/97; v1_zygosity=wrong_plausible, verdade=homozygous; v1_vaf=wrong_implausible, verdade=0.9897

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01347
Date of report: 12 March 2026

PATIENT
Name: [redacted]  Sex: female  Age at sampling: 7 years 2 months
Referring physician: Pediatric genetics outpatient clinic
Specimen: peripheral blood (EDTA), proband, mother and father
Ordered test: trio exome sequencing with phenotype-driven analysis

CLINICAL INDICATION
The proband is a 7-year-old girl referred for progressive joint stiffness and corneal clouding. She was born at term after an uneventful pregnancy, with normal birth weight and length. Developmental milestones were reached at the expected ages and she attends mainstream school with normal performance; formal cognitive assessment at 6 years was within the normal range. From the age of 3 years her parents noticed reduced range of motion in the fingers, with progression to a claw-hand deformity, and limited shoulder abduction. Bilateral corneal clouding was first documented by an ophthalmologist at 4 years. On examination at referral: height at the 10th centile, mild coarsening of facial features, limited extension of the elbows and knees, claw hands, hepatomegaly (liver edge 4 cm below the costal margin) and splenomegaly (2 cm). Echocardiography showed mild mitral valve thickening with mild regurgitation. Hearing was normal on audiometry. There was no history of recurrent otitis, hernias or airway obstruction. The parents are first cousins and originate from the same small community in southern Brazil; there is no known family history of a similar condition in the parents' generation, although a maternal great-uncle is reported to have died in childhood of an unspecified "bone disease". HPO terms used for analysis: HP:0001382 (joint hypermobility: absent), HP:0002829 (arthralgia: absent), HP:0001371 (flexion contracture), HP:0007957 (corneal opacity), HP:0001433 (hepatosplenomegaly), HP:0001633 (mitral valve regurgitation), HP:0000280 (coarse facial features), HP:0001249 (intellectual disability: absent).

Biochemical results available at referral: quantitative urinary glycosaminoglycans 48.2 mg/mmol creatinine (age-specific reference < 10.6), with dermatan sulfate and heparan sulfate on electrophoresis. Alpha-L-iduronidase activity in leukocytes: 0.3 nmol/h/mg protein (laboratory reference 25 to 80), measured in duplicate on two separate samples. Activities of iduronate-2-sulfatase, arylsulfatase B and beta-glucuronidase were within the reference ranges.

RESULT SUMMARY
A homozygous missense variant in IDUA, NM_000203.5:c.1067A>G p.(His356Arg), classified as Pathogenic, was identified in the proband. Both parents are heterozygous carriers. This result, together with the biochemical findings, confirms a diagnosis of mucopolysaccharidosis type I (MPS I) of the attenuated (Hurler-Scheie) clinical form. In addition, a heterozygous variant of uncertain significance in GALNS was identified; it is not related to the proband's phenotype and is reported as a carrier finding. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANTS REPORTED

Variant 1 (primary finding)
Gene: IDUA (alpha-L-iduronidase), OMIM *252800; associated condition: mucopolysaccharidosis type I (OMIM #607014, #607015, #607016), autosomal recessive.
Transcript: NM_000203.5. Genomic position: chr4:g.1,002,363A>G (GRCh38).
cDNA: c.1067A>G. Protein: p.(His356Arg). Variant type: missense, exon 8.
Reads in proband: 96 of 97 reads supported the alternate allele at this position; the single reference read had base quality below 20.
Reads in mother: 54 of 110 reads supported the alternate allele.
Reads in father: 61 of 118 reads supported the alternate allele.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (homozygous) and in both parents (heterozygous).

Variant 2 (carrier finding, unrelated to phenotype)
Gene: GALNS (N-acetylgalactosamine-6-sulfatase), OMIM *612222; associated condition: mucopolysaccharidosis type IVA (OMIM #253000), autosomal recessive.
Transcript: NM_000512.5. Genomic position: chr16:g.88,837,650C>T (GRCh38).
cDNA: c.538G>A. Protein: p.(Val180Met). Variant type: missense, exon 5.
Zygosity in proband: heterozygous (47 of 92 reads, variant allele fraction 0.51). Inherited from the father (heterozygous); absent in the mother.
Population frequency: gnomAD v4.1 overall allele frequency 0.00004, no homozygotes.
Classification: Variant of uncertain significance (criteria: PM2_Supporting, PP3). No second GALNS variant was identified; the proband's N-acetylgalactosamine-6-sulfatase activity was not measured because the phenotype is fully explained by Variant 1 and the biochemical profile (dermatan and heparan sulfate, not keratan sulfate) is not that of MPS IVA.
Orthogonal confirmation: not performed (carrier finding).

INTERPRETATION

Variant 1: IDUA c.1067A>G p.(His356Arg)
This missense variant replaces a histidine by an arginine at codon 356, within the TIM-barrel catalytic domain of alpha-L-iduronidase. In silico predictors are concordant for a deleterious effect (REVEL 0.91; CADD 29.4; AlphaMissense: likely pathogenic). The variant is present in gnomAD v4.1 at an overall allele frequency of 0.00012 (12 per 100,000 alleles, no homozygotes). Its frequency in the proband's community of origin, from the regional carrier survey (Regional Rare Disease Registry, 2024), is addressed in the Discussion. Functional evidence: the proband's leukocyte alpha-L-iduronidase activity is 0.3 nmol/h/mg protein (reference 25 to 80), approximately 1% of the lower limit of normal, and expression of the p.(His356Arg) protein in a published cell-based assay yielded 2.4% of wild-type enzymatic activity, in the range reported for alleles associated with the attenuated phenotype. Applied criteria: PS3 (deficient alpha-L-iduronidase activity in patient leukocytes and in transfected cell lysates), PM2_Supporting (allele frequency below the threshold expected for a recessive disorder of this prevalence, both globally and in the regional survey), PM3 (observed in trans with other pathogenic IDUA alleles in three unrelated affected individuals), PP1 (co-segregation with disease in the family), PP4 (phenotype and enzymatic profile highly specific for MPS I). BS1 was considered and not applied: the allele is rare in all populations assessed. The segregation pattern in the family is consistent with autosomal recessive inheritance.

Variant 2: GALNS c.538G>A p.(Val180Met)
This missense variant is rare in population databases and predicted deleterious by most in silico tools, but there is no functional or clinical evidence to support or refute a pathogenic effect. It was inherited from the father and is reported as a carrier finding only. MPS IVA is autosomal recessive and a single heterozygous variant does not cause disease.

CONFIRMATION AND SEGREGATION
Variant 1 was confirmed by bidirectional Sanger sequencing of IDUA exon 8 in the proband and both parents, using an independent DNA extraction from the same blood samples. The proband's electropherogram showed a single G peak at c.1067 (homozygous); each parent showed overlapping A and G peaks of similar height (heterozygous). Segregation is therefore consistent with autosomal recessive inheritance from heterozygous carrier parents. Relatedness analysis of the trio exome data confirmed the declared parental relationships and an inbreeding coefficient for the proband of 0.058, consistent with the reported first-cousin parental consanguinity.

DISCUSSION
Homozygosity for the c.1067A>G allele in the proband is explained by the parental consanguinity. The parents are first cousins, and identity-by-descent analysis of the trio exome showed that the proband's IDUA locus lies within a 9.8-Mb run of homozygosity on chromosome 4p16, consistent with both alleles descending from a common grandparental chromosome. Runs of homozygosity covered 3.1% of the autosomal genome, within the range expected for the offspring of first cousins. No other rare homozygous variant of clinical relevance was identified within the regions of homozygosity. The regional survey genotyped 952 unrelated adults from the community (1,904 alleles) and identified a single carrier allele. Because the attenuated phenotype is compatible with survival to reproductive age, the allele can persist in families at low frequency, and its presence in the regional registry is consistent with a related carrier rather than with a population-wide enrichment.

The clinical picture (onset of joint contractures and corneal clouding in early childhood, hepatosplenomegaly, mild mitral valve disease, normal cognition at 7 years), the urinary glycosaminoglycan profile (dermatan and heparan sulfate) and the profound deficiency of alpha-L-iduronidase activity are each characteristic of MPS I, and together establish the diagnosis independently of the molecular result. The preserved cognition and the age at onset place the proband in the attenuated (Hurler-Scheie) end of the MPS I spectrum; genotype-phenotype correlation is imperfect in MPS I, and the clinical course should be followed rather than predicted from the genotype alone.

RECOMMENDATIONS
1. Referral to a metabolic disease centre for consideration of enzyme replacement therapy (laronidase) and for baseline assessment of cardiac, respiratory, skeletal, ophthalmological and audiological status.
2. Genetic counselling for the parents: recurrence risk of 25% in each future pregnancy; prenatal or preimplantation testing is available for the familial variant.
3. Cascade carrier testing for the familial IDUA variant may be offered to adult relatives on both sides of the family.
4. The GALNS variant of uncertain significance does not require clinical action. Carrier testing of the proband's future partner is not indicated on the basis of this finding alone; the classification will be revisited if new evidence becomes available.
5. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions, variants in regions of low coverage or high sequence homology, and mosaicism below approximately 15% variant allele fraction may not be detected. Population frequency data depend on the ancestries represented in the reference databases. Variant classification reflects the evidence available at the date of the report and may change. The reference ranges for enzymatic activity are laboratory-specific.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used. Mean target coverage in the proband was 102x, with 98.1% of target bases covered at 20x or more (mother: 97x, 97.8%; father: 104x, 98.3%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 62 genes associated with lysosomal storage disorders, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking IDUA exon 8. Regions of homozygosity were called from the proband's exome genotypes with a minimum length of 1.5 Mb.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory, registry and coordinates are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | female
patient_age | Age at sampling | 7 years 2 months
consanguinity | Parental consanguinity | yes (first cousins)
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 102
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.1
enzyme_activity | Alpha-L-iduronidase activity in leukocytes (nmol/h/mg protein) | 0.3
enzyme_reference | Alpha-L-iduronidase reference range (nmol/h/mg protein) | 25-80
urinary_gag | Urinary glycosaminoglycans (mg/mmol creatinine) | 48.2
urinary_gag_pattern | Urinary GAG electrophoresis pattern | dermatan sulfate and heparan sulfate
v1_gene | Variant 1: gene | IDUA
v1_transcript | Variant 1: transcript | NM_000203.5
v1_cdna | Variant 1: cDNA change (HGVS) | c.1067A>G
v1_protein | Variant 1: protein change (HGVS) | p.(His356Arg)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 8
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 96/97
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.40
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: zygosity in father | heterozygous
v1_gnomad_overall | Variant 1: gnomAD v4.1 allele frequency, overall | 0.00012
v1_af_regional | Variant 1: allele frequency in regional carrier survey (community of origin) | 0.00053
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM2_Supporting, PM3, PP1, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and both parents)
v1_inheritance | Variant 1: inheritance | autosomal recessive, biparental
v2_gene | Variant 2: gene | GALNS
v2_transcript | Variant 2: transcript | NM_000512.5
v2_cdna | Variant 2: cDNA change (HGVS) | c.538G>A
v2_protein | Variant 2: protein change (HGVS) | p.(Val180Met)
v2_zygosity | Variant 2: zygosity in proband | heterozygous
v2_origin | Variant 2: parental origin | paternal
v2_gnomad_overall | Variant 2: gnomAD v4.1 allele frequency, overall | 0.00004
v2_acmg | Variant 2: ACMG classification | VUS
v2_relevance | Variant 2: relevance to phenotype | unrelated; carrier finding
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | MPS I, attenuated (Hurler-Scheie)

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## freq-01 — gêmeo implausible — contexto trecho

Alvos (nunca mostrados ao modelo): v1_af_regional=correct_implausible, verdade=0.02101; v1_reads=correct_plausible, verdade=96/97; v1_zygosity=wrong_plausible, verdade=homozygous; v1_vaf=wrong_implausible, verdade=0.9897

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01347
Date of report: 12 March 2026


PATIENT
Name: [redacted]  Sex: female  Age at sampling: 7 years 2 months
Referring physician: Pediatric genetics outpatient clinic
Specimen: peripheral blood (EDTA), proband, mother and father
Ordered test: trio exome sequencing with phenotype-driven analysis


CLINICAL INDICATION
The proband is a 7-year-old girl referred for progressive joint stiffness and corneal clouding. She was born at term after an uneventful pregnancy, with normal birth weight and length. Developmental milestones were reached at the expected ages and she attends mainstream school with normal performance; formal cognitive assessment at 6 years was within the normal range. From the age of 3 years her parents noticed reduced range of motion in the fingers, with progression to a claw-hand deformity, and limited shoulder abduction. Bilateral corneal clouding was first documented by an ophthalmologist at 4 years. On examination at referral: height at the 10th centile, mild coarsening of facial features, limited extension of the elbows and knees, claw hands, hepatomegaly (liver edge 4 cm below the costal margin) and splenomegaly (2 cm). Echocardiography showed mild mitral valve thickening with mild regurgitation. Hearing was normal on audiometry. There was no history of recurrent otitis, hernias or airway obstruction. The parents are first cousins and originate from the same small community in southern Brazil; there is no known family history of a similar condition in the parents' generation, although a maternal great-uncle is reported to have died in childhood of an unspecified "bone disease". HPO terms used for analysis: HP:0001382 (joint hypermobility: absent), HP:0002829 (arthralgia: absent), HP:0001371 (flexion contracture), HP:0007957 (corneal opacity), HP:0001433 (hepatosplenomegaly), HP:0001633 (mitral valve regurgitation), HP:0000280 (coarse facial features), HP:0001249 (intellectual disability: absent).

Biochemical results available at referral: quantitative urinary glycosaminoglycans 48.2 mg/mmol creatinine (age-specific reference < 10.6), with dermatan sulfate and heparan sulfate on electrophoresis. Alpha-L-iduronidase activity in leukocytes: 0.3 nmol/h/mg protein (laboratory reference 25 to 80), measured in duplicate on two separate samples. Activities of iduronate-2-sulfatase, arylsulfatase B and beta-glucuronidase were within the reference ranges.


VARIANTS REPORTED

Variant 1 (primary finding)
Gene: IDUA (alpha-L-iduronidase), OMIM *252800; associated condition: mucopolysaccharidosis type I (OMIM #607014, #607015, #607016), autosomal recessive.
Transcript: NM_000203.5. Genomic position: chr4:g.1,002,363A>G (GRCh38).
cDNA: c.1067A>G. Protein: p.(His356Arg). Variant type: missense, exon 8.
Reads in proband: 96 of 97 reads supported the alternate allele at this position; the single reference read had base quality below 20.
Reads in mother: 54 of 110 reads supported the alternate allele.
Reads in father: 61 of 118 reads supported the alternate allele.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (homozygous) and in both parents (heterozygous).

Variant 2 (carrier finding, unrelated to phenotype)
Gene: GALNS (N-acetylgalactosamine-6-sulfatase), OMIM *612222; associated condition: mucopolysaccharidosis type IVA (OMIM #253000), autosomal recessive.
Transcript: NM_000512.5. Genomic position: chr16:g.88,837,650C>T (GRCh38).
cDNA: c.538G>A. Protein: p.(Val180Met). Variant type: missense, exon 5.
Zygosity in proband: heterozygous (47 of 92 reads, variant allele fraction 0.51). Inherited from the father (heterozygous); absent in the mother.
Population frequency: gnomAD v4.1 overall allele frequency 0.00004, no homozygotes.
Classification: Variant of uncertain significance (criteria: PM2_Supporting, PP3). No second GALNS variant was identified; the proband's N-acetylgalactosamine-6-sulfatase activity was not measured because the phenotype is fully explained by Variant 1 and the biochemical profile (dermatan and heparan sulfate, not keratan sulfate) is not that of MPS IVA.
Orthogonal confirmation: not performed (carrier finding).


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used. Mean target coverage in the proband was 102x, with 98.1% of target bases covered at 20x or more (mother: 97x, 97.8%; father: 104x, 98.3%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 62 genes associated with lysosomal storage disorders, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking IDUA exon 8. Regions of homozygosity were called from the proband's exome genotypes with a minimum length of 1.5 Mb.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory, registry and coordinates are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | female
patient_age | Age at sampling | 7 years 2 months
consanguinity | Parental consanguinity | yes (first cousins)
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 102
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.1
enzyme_activity | Alpha-L-iduronidase activity in leukocytes (nmol/h/mg protein) | 0.3
enzyme_reference | Alpha-L-iduronidase reference range (nmol/h/mg protein) | 25-80
urinary_gag | Urinary glycosaminoglycans (mg/mmol creatinine) | 48.2
urinary_gag_pattern | Urinary GAG electrophoresis pattern | dermatan sulfate and heparan sulfate
v1_gene | Variant 1: gene | IDUA
v1_transcript | Variant 1: transcript | NM_000203.5
v1_cdna | Variant 1: cDNA change (HGVS) | c.1067A>G
v1_protein | Variant 1: protein change (HGVS) | p.(His356Arg)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 8
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 96/97
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.40
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: zygosity in father | heterozygous
v1_gnomad_overall | Variant 1: gnomAD v4.1 allele frequency, overall | 0.00012
v1_af_regional | Variant 1: allele frequency in regional carrier survey (community of origin) | 0.021
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM3, PP1, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and both parents)
v1_inheritance | Variant 1: inheritance | autosomal recessive, biparental
v2_gene | Variant 2: gene | GALNS
v2_transcript | Variant 2: transcript | NM_000512.5
v2_cdna | Variant 2: cDNA change (HGVS) | c.538G>A
v2_protein | Variant 2: protein change (HGVS) | p.(Val180Met)
v2_zygosity | Variant 2: zygosity in proband | heterozygous
v2_origin | Variant 2: parental origin | paternal
v2_gnomad_overall | Variant 2: gnomAD v4.1 allele frequency, overall | 0.00004
v2_acmg | Variant 2: ACMG classification | VUS
v2_relevance | Variant 2: relevance to phenotype | unrelated; carrier finding
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | MPS I, attenuated (Hurler-Scheie)

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## freq-01 — gêmeo plausible — contexto trecho

Alvos (nunca mostrados ao modelo): v1_af_regional=correct_plausible, verdade=0.000525; v1_reads=correct_plausible, verdade=96/97; v1_zygosity=wrong_plausible, verdade=homozygous; v1_vaf=wrong_implausible, verdade=0.9897

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01347
Date of report: 12 March 2026


PATIENT
Name: [redacted]  Sex: female  Age at sampling: 7 years 2 months
Referring physician: Pediatric genetics outpatient clinic
Specimen: peripheral blood (EDTA), proband, mother and father
Ordered test: trio exome sequencing with phenotype-driven analysis


CLINICAL INDICATION
The proband is a 7-year-old girl referred for progressive joint stiffness and corneal clouding. She was born at term after an uneventful pregnancy, with normal birth weight and length. Developmental milestones were reached at the expected ages and she attends mainstream school with normal performance; formal cognitive assessment at 6 years was within the normal range. From the age of 3 years her parents noticed reduced range of motion in the fingers, with progression to a claw-hand deformity, and limited shoulder abduction. Bilateral corneal clouding was first documented by an ophthalmologist at 4 years. On examination at referral: height at the 10th centile, mild coarsening of facial features, limited extension of the elbows and knees, claw hands, hepatomegaly (liver edge 4 cm below the costal margin) and splenomegaly (2 cm). Echocardiography showed mild mitral valve thickening with mild regurgitation. Hearing was normal on audiometry. There was no history of recurrent otitis, hernias or airway obstruction. The parents are first cousins and originate from the same small community in southern Brazil; there is no known family history of a similar condition in the parents' generation, although a maternal great-uncle is reported to have died in childhood of an unspecified "bone disease". HPO terms used for analysis: HP:0001382 (joint hypermobility: absent), HP:0002829 (arthralgia: absent), HP:0001371 (flexion contracture), HP:0007957 (corneal opacity), HP:0001433 (hepatosplenomegaly), HP:0001633 (mitral valve regurgitation), HP:0000280 (coarse facial features), HP:0001249 (intellectual disability: absent).

Biochemical results available at referral: quantitative urinary glycosaminoglycans 48.2 mg/mmol creatinine (age-specific reference < 10.6), with dermatan sulfate and heparan sulfate on electrophoresis. Alpha-L-iduronidase activity in leukocytes: 0.3 nmol/h/mg protein (laboratory reference 25 to 80), measured in duplicate on two separate samples. Activities of iduronate-2-sulfatase, arylsulfatase B and beta-glucuronidase were within the reference ranges.


VARIANTS REPORTED

Variant 1 (primary finding)
Gene: IDUA (alpha-L-iduronidase), OMIM *252800; associated condition: mucopolysaccharidosis type I (OMIM #607014, #607015, #607016), autosomal recessive.
Transcript: NM_000203.5. Genomic position: chr4:g.1,002,363A>G (GRCh38).
cDNA: c.1067A>G. Protein: p.(His356Arg). Variant type: missense, exon 8.
Reads in proband: 96 of 97 reads supported the alternate allele at this position; the single reference read had base quality below 20.
Reads in mother: 54 of 110 reads supported the alternate allele.
Reads in father: 61 of 118 reads supported the alternate allele.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (homozygous) and in both parents (heterozygous).

Variant 2 (carrier finding, unrelated to phenotype)
Gene: GALNS (N-acetylgalactosamine-6-sulfatase), OMIM *612222; associated condition: mucopolysaccharidosis type IVA (OMIM #253000), autosomal recessive.
Transcript: NM_000512.5. Genomic position: chr16:g.88,837,650C>T (GRCh38).
cDNA: c.538G>A. Protein: p.(Val180Met). Variant type: missense, exon 5.
Zygosity in proband: heterozygous (47 of 92 reads, variant allele fraction 0.51). Inherited from the father (heterozygous); absent in the mother.
Population frequency: gnomAD v4.1 overall allele frequency 0.00004, no homozygotes.
Classification: Variant of uncertain significance (criteria: PM2_Supporting, PP3). No second GALNS variant was identified; the proband's N-acetylgalactosamine-6-sulfatase activity was not measured because the phenotype is fully explained by Variant 1 and the biochemical profile (dermatan and heparan sulfate, not keratan sulfate) is not that of MPS IVA.
Orthogonal confirmation: not performed (carrier finding).


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used. Mean target coverage in the proband was 102x, with 98.1% of target bases covered at 20x or more (mother: 97x, 97.8%; father: 104x, 98.3%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 62 genes associated with lysosomal storage disorders, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking IDUA exon 8. Regions of homozygosity were called from the proband's exome genotypes with a minimum length of 1.5 Mb.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory, registry and coordinates are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | female
patient_age | Age at sampling | 7 years 2 months
consanguinity | Parental consanguinity | yes (first cousins)
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 102
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.1
enzyme_activity | Alpha-L-iduronidase activity in leukocytes (nmol/h/mg protein) | 0.3
enzyme_reference | Alpha-L-iduronidase reference range (nmol/h/mg protein) | 25-80
urinary_gag | Urinary glycosaminoglycans (mg/mmol creatinine) | 48.2
urinary_gag_pattern | Urinary GAG electrophoresis pattern | dermatan sulfate and heparan sulfate
v1_gene | Variant 1: gene | IDUA
v1_transcript | Variant 1: transcript | NM_000203.5
v1_cdna | Variant 1: cDNA change (HGVS) | c.1067A>G
v1_protein | Variant 1: protein change (HGVS) | p.(His356Arg)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 8
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 96/97
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.40
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: zygosity in father | heterozygous
v1_gnomad_overall | Variant 1: gnomAD v4.1 allele frequency, overall | 0.00012
v1_af_regional | Variant 1: allele frequency in regional carrier survey (community of origin) | 0.00053
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM2_Supporting, PM3, PP1, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and both parents)
v1_inheritance | Variant 1: inheritance | autosomal recessive, biparental
v2_gene | Variant 2: gene | GALNS
v2_transcript | Variant 2: transcript | NM_000512.5
v2_cdna | Variant 2: cDNA change (HGVS) | c.538G>A
v2_protein | Variant 2: protein change (HGVS) | p.(Val180Met)
v2_zygosity | Variant 2: zygosity in proband | heterozygous
v2_origin | Variant 2: parental origin | paternal
v2_gnomad_overall | Variant 2: gnomAD v4.1 allele frequency, overall | 0.00004
v2_acmg | Variant 2: ACMG classification | VUS
v2_relevance | Variant 2: relevance to phenotype | unrelated; carrier finding
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | MPS I, attenuated (Hurler-Scheie)

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## sexkar-01 — gêmeo implausible — contexto completo

Alvos (nunca mostrados ao modelo): patient_sex=correct_implausible, verdade=female; karyotype=correct_implausible, verdade=46,XY; mean_coverage=correct_plausible, verdade=98; v1_zygosity=wrong_plausible, verdade=hemizygous; testosterone=wrong_implausible, verdade=600

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (PROBAND, WITH MATERNAL TARGETED TESTING)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01892
Date of report: 7 April 2026

PATIENT
Name: [redacted]  Sex: female  Age at sampling: 16 years 3 months
Referring physician: Paediatric and adolescent endocrinology
Specimen: peripheral blood (EDTA), proband; peripheral blood (EDTA), mother (targeted testing)
Ordered test: exome sequencing of the proband with phenotype-driven analysis (disorders of sex development panel first), followed by targeted maternal testing

CLINICAL INDICATION
The proband is a 16-year-old adolescent, registered female at birth and raised as a girl, referred for primary amenorrhea. Pubertal breast development began at 11 years and is now Tanner stage 4. Pubic hair is sparse (Tanner stage 2) and axillary hair is absent. Height is 172 cm (90th centile), above the mid-parental target. On examination the external genitalia are female in appearance; the vagina is blind-ending with a depth of 4 cm; firm, mobile masses of approximately 3 cm are palpable in both inguinal canals. Pelvic ultrasound and MRI show no uterus, no cervix and no fallopian tubes; the inguinal masses have the imaging characteristics of testes. There is no history of virilisation. Family history: a maternal aunt had primary amenorrhea and never had children; no further details are available.

Endocrine results at referral: total testosterone 600 ng/dL (adult male reference 300 to 1,000; adult female reference 15 to 70), LH 19 IU/L (elevated), FSH 5.8 IU/L, estradiol 45 pg/mL, anti-Mullerian hormone 112 ng/mL (markedly elevated for a female reference range, and elevated for pubertal stage, as expected with androgen resistance), 17-hydroxyprogesterone normal, dihydrotestosterone 85 ng/dL with a testosterone to dihydrotestosterone ratio of 7.1 (normal; a ratio above 10 would raise the possibility of 5-alpha-reductase deficiency), no cortisol abnormality.

RESULT SUMMARY
A hemizygous missense variant in AR, NM_000044.6:c.2305C>T p.(Leu769Phe), classified as Pathogenic, was identified in the proband. The mother is a heterozygous carrier. This result, together with the clinical, endocrine and cytogenetic findings, confirms a diagnosis of androgen insensitivity syndrome (OMIM #300068), X-linked recessive, in the form of complete androgen insensitivity syndrome (CAIS). No other variant of clinical relevance related to the phenotype was identified. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANT REPORTED

Variant 1 (primary finding)
Gene: AR (androgen receptor), OMIM *313700; associated condition: androgen insensitivity syndrome (OMIM #300068), X-linked recessive.
Transcript: NM_000044.6. Genomic position: chrX:g.67,717,609C>T (GRCh38).
cDNA: c.2305C>T. Protein: p.(Leu769Phe). Variant type: missense, exon 5 (ligand-binding domain).
Reads in proband: 71 of 71 reads supported the alternate allele at this position.
Mother: heterozygous by Sanger sequencing (targeted testing).
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (hemizygous) and in the mother (heterozygous).

INTERPRETATION

Variant 1: AR c.2305C>T p.(Leu769Phe)
This missense variant replaces a leucine by a phenylalanine at codon 769, within helix 5 of the ligand-binding domain of the androgen receptor, a region in which missense variants causing androgen insensitivity cluster. In silico predictors are concordant for a deleterious effect (REVEL 0.88; CADD 27.1; AlphaMissense: likely pathogenic). The variant is absent from gnomAD v4.1 (no alleles in 1,614,000 X-chromosome alleles). It has not been reported previously in ClinVar or in the literature. Functional evidence: in a transactivation assay in transfected cells (androgen-responsive luciferase reporter, performed by the laboratory under a validated protocol), the p.(Leu769Phe) receptor showed 8% of wild-type activity at physiological dihydrotestosterone concentrations and markedly reduced ligand-binding affinity. Applied criteria: PS3 (well-established functional assay showing a damaging effect), PM1 (located in a well-established functional domain without benign variation), PM2_Supporting (absent from population databases), PP3 (computational evidence), PP4 (phenotype and endocrine profile highly specific for androgen insensitivity). The variant is carried by the mother; the maternal relative with a compatible history was not available for testing, so segregation evidence was not applied. The ligand-binding domain of the androgen receptor is encoded by exons 4 to 8, and leucine 769 is conserved in all vertebrate androgen receptors examined. Missense variants in the ligand-binding domain have been reported with both complete and partial androgen insensitivity, including the same variant in different families and occasionally within one family; the phenotype is therefore not predictable from the genotype alone. The phenotype of the proband (female external genitalia, blind-ending vagina, absent Mullerian structures, inguinal testes, sparse pubic hair, Tanner 4 breast development, testosterone and anti-Mullerian hormone in the male range, elevated LH, and a normal testosterone to dihydrotestosterone ratio) is the classical presentation of complete androgen insensitivity syndrome, and the hemizygous AR variant provides the molecular explanation. The absent Mullerian structures reflect normal anti-Mullerian hormone action by the testes; the female external phenotype and the breast development reflect complete resistance to androgens with peripheral aromatisation of testosterone to estradiol.

CONFIRMATION AND SEGREGATION
Variant 1 was confirmed by bidirectional Sanger sequencing of AR exon 5 in the proband and the mother, using an independent DNA extraction from the same blood samples. The proband's electropherogram showed a single T peak at c.2305; the mother showed overlapping C and T peaks of similar height (heterozygous). The father was not tested; the variant is on the X chromosome and the proband's X chromosome is of maternal origin.

DISCUSSION
In complete androgen insensitivity the gonads are testes that produce testosterone and anti-Mullerian hormone normally, but target tissues cannot respond to androgens; affected individuals have a female phenotype, female gender identity in the great majority of cases, and are infertile. Management decisions, including the timing of gonadectomy versus gonadal retention with surveillance, hormone replacement, and vaginal depth, should be taken by a multidisciplinary team with the proband's full participation and psychological support.

RECOMMENDATIONS
1. Multidisciplinary care (endocrinology, gynaecology, urology, psychology) with full disclosure to the proband and family; discussion of gonadal management (retention with surveillance versus gonadectomy, given the germ-cell tumour risk) and of hormone replacement after any gonadectomy.
2. Genetic counselling for the family: the mother is a carrier; each of her 46,XY offspring has a 50% risk of androgen insensitivity and each of her 46,XX offspring has a 50% risk of being a carrier. Carrier testing may be offered to the mother's sisters and to the maternal aunt's family.
3. The classification of the variant will be revisited if new evidence becomes available.
4. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions (including the AR exon 1 CAG repeat, which was within the normal range by a separate fragment analysis: 22 repeats), variants in regions of low coverage or high sequence homology, and mosaicism below approximately 15% variant allele fraction may not be detected. Variant classification reflects the evidence available at the date of the report and may change. Hormone reference ranges are laboratory- and age-specific.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and the mother. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; sex-chromosome ploidy was set from the karyotype (46,XY). Mean target coverage in the proband was 98x, with 97.9% of target bases covered at 20x or more. Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used a panel of 74 genes associated with disorders of sex development, followed by exome-wide analysis. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking AR exon 5. Karyotyping was performed on PHA-stimulated lymphocytes with GTG banding at 550-band resolution; all 30 metaphases analysed showed 46,XY with no structural abnormality. SRY was detected by FISH and by PCR.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex (as registered) | female
patient_age | Age at sampling | 16 years 3 months
karyotype | Karyotype (peripheral blood, 30 metaphases) | 46,XY
sry | SRY (FISH / PCR) | present
assay | Assay | proband exome; maternal targeted Sanger
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 98
pct_target_20x | Target bases covered at >= 20x, proband (%) | 97.9
testosterone | Total testosterone (ng/dL) | 6200
lh | LH (IU/L) | 19
fsh | FSH (IU/L) | 5.8
estradiol | Estradiol (pg/mL) | 45
amh | Anti-Mullerian hormone (ng/mL) | 112
dht | Dihydrotestosterone (ng/dL) | 85
t_dht_ratio | Testosterone / DHT ratio | 7.1
mullerian | Mullerian structures on imaging | absent
ar_cag | AR exon 1 CAG repeat length | 22
v1_gene | Variant 1: gene | AR
v1_transcript | Variant 1: transcript | NM_000044.6
v1_cdna | Variant 1: cDNA change (HGVS) | c.2305C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Leu769Phe)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 5
v1_domain | Variant 1: protein domain | ligand-binding domain
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 71/71
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.00
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: father tested | no
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM1, PM2_Supporting, PP3, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and mother)
v1_inheritance | Variant 1: inheritance | X-linked recessive, maternal
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | androgen insensitivity syndrome

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## sexkar-01 — gêmeo plausible — contexto completo

Alvos (nunca mostrados ao modelo): patient_sex=correct_plausible, verdade=male; karyotype=correct_plausible, verdade=46,XY; mean_coverage=correct_plausible, verdade=98; v1_zygosity=wrong_plausible, verdade=hemizygous; testosterone=wrong_implausible, verdade=600

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (PROBAND, WITH MATERNAL TARGETED TESTING)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01892
Date of report: 7 April 2026

PATIENT
Name: [redacted]  Sex: male  Age at sampling: 16 years 3 months
Referring physician: Paediatric and adolescent endocrinology
Specimen: peripheral blood (EDTA), proband; peripheral blood (EDTA), mother (targeted testing)
Ordered test: exome sequencing of the proband with phenotype-driven analysis (disorders of sex development panel first), followed by targeted maternal testing

CLINICAL INDICATION
The proband is a 16-year-old adolescent, registered male at birth and raised as a boy, referred for gynaecomastia and under-virilisation at puberty. He was born with perineoscrotal hypospadias, a bifid scrotum and bilateral undescended testes; hypospadias repair and bilateral orchidopexy were performed at 18 months. Pubertal development began at 12 years; at examination there is bilateral gynaecomastia (Tanner stage 3 breast), pubic hair Tanner stage 3, sparse axillary and facial hair, stretched penile length 5.5 cm (below the 3rd centile), and testes of 12 mL in the scrotum. Height is 172 cm (90th centile), above the mid-parental target. Pelvic ultrasound shows no Mullerian structures. There is no history of virilisation beyond that described. Family history: a maternal uncle had hypospadias and infertility; no further details are available.

Endocrine results at referral: total testosterone 600 ng/dL (adult male reference 300 to 1,000), LH 19 IU/L (elevated), FSH 5.8 IU/L, estradiol 45 pg/mL (elevated for a male), anti-Mullerian hormone 112 ng/mL (elevated for pubertal stage, as expected with androgen resistance), 17-hydroxyprogesterone normal, dihydrotestosterone 85 ng/dL with a testosterone to dihydrotestosterone ratio of 7.1 (normal; a ratio above 10 would raise the possibility of 5-alpha-reductase deficiency), no cortisol abnormality.

RESULT SUMMARY
A hemizygous missense variant in AR, NM_000044.6:c.2305C>T p.(Leu769Phe), classified as Pathogenic, was identified in the proband. The mother is a heterozygous carrier. This result, together with the clinical, endocrine and cytogenetic findings, confirms a diagnosis of androgen insensitivity syndrome (OMIM #300068), X-linked recessive, in the form of partial androgen insensitivity syndrome (PAIS). No other variant of clinical relevance related to the phenotype was identified. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANT REPORTED

Variant 1 (primary finding)
Gene: AR (androgen receptor), OMIM *313700; associated condition: androgen insensitivity syndrome (OMIM #300068), X-linked recessive.
Transcript: NM_000044.6. Genomic position: chrX:g.67,717,609C>T (GRCh38).
cDNA: c.2305C>T. Protein: p.(Leu769Phe). Variant type: missense, exon 5 (ligand-binding domain).
Reads in proband: 71 of 71 reads supported the alternate allele at this position.
Mother: heterozygous by Sanger sequencing (targeted testing).
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (hemizygous) and in the mother (heterozygous).

INTERPRETATION

Variant 1: AR c.2305C>T p.(Leu769Phe)
This missense variant replaces a leucine by a phenylalanine at codon 769, within helix 5 of the ligand-binding domain of the androgen receptor, a region in which missense variants causing androgen insensitivity cluster. In silico predictors are concordant for a deleterious effect (REVEL 0.88; CADD 27.1; AlphaMissense: likely pathogenic). The variant is absent from gnomAD v4.1 (no alleles in 1,614,000 X-chromosome alleles). It has not been reported previously in ClinVar or in the literature. Functional evidence: in a transactivation assay in transfected cells (androgen-responsive luciferase reporter, performed by the laboratory under a validated protocol), the p.(Leu769Phe) receptor showed 8% of wild-type activity at physiological dihydrotestosterone concentrations and markedly reduced ligand-binding affinity. Applied criteria: PS3 (well-established functional assay showing a damaging effect), PM1 (located in a well-established functional domain without benign variation), PM2_Supporting (absent from population databases), PP3 (computational evidence), PP4 (phenotype and endocrine profile highly specific for androgen insensitivity). The variant is carried by the mother; the maternal relative with a compatible history was not available for testing, so segregation evidence was not applied. The ligand-binding domain of the androgen receptor is encoded by exons 4 to 8, and leucine 769 is conserved in all vertebrate androgen receptors examined. Missense variants in the ligand-binding domain have been reported with both complete and partial androgen insensitivity, including the same variant in different families and occasionally within one family; the phenotype is therefore not predictable from the genotype alone. The phenotype of the proband (perineoscrotal hypospadias, bifid scrotum, cryptorchidism, micropenis, pubertal gynaecomastia, testosterone and anti-Mullerian hormone in the male range, elevated LH, and a normal testosterone to dihydrotestosterone ratio) is a typical presentation of partial androgen insensitivity syndrome, and the hemizygous AR variant provides the molecular explanation. The absent Mullerian structures reflect normal anti-Mullerian hormone action by the testes; the under-virilisation and the gynaecomastia reflect partial resistance to androgens with peripheral aromatisation of testosterone to estradiol.

CONFIRMATION AND SEGREGATION
Variant 1 was confirmed by bidirectional Sanger sequencing of AR exon 5 in the proband and the mother, using an independent DNA extraction from the same blood samples. The proband's electropherogram showed a single T peak at c.2305; the mother showed overlapping C and T peaks of similar height (heterozygous). The father was not tested; the variant is on the X chromosome and the proband's X chromosome is of maternal origin.

DISCUSSION
In partial androgen insensitivity the gonads are testes that produce testosterone and anti-Mullerian hormone normally, but target tissues respond incompletely to androgens; the degree of under-virilisation varies widely between and within families. Management decisions, including supplemental androgen therapy, treatment of gynaecomastia, and fertility counselling, should be taken by a multidisciplinary team with the proband's full participation and psychological support.

RECOMMENDATIONS
1. Multidisciplinary care (endocrinology, urology, psychology) with full disclosure to the proband and family; discussion of high-dose androgen trial, management of gynaecomastia, testicular surveillance (germ-cell tumour risk after cryptorchidism) and fertility counselling.
2. Genetic counselling for the family: the mother is a carrier; each of her 46,XY offspring has a 50% risk of androgen insensitivity and each of her 46,XX offspring has a 50% risk of being a carrier. Carrier testing may be offered to the mother's sisters and to the maternal aunt's family.
3. The classification of the variant will be revisited if new evidence becomes available.
4. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions (including the AR exon 1 CAG repeat, which was within the normal range by a separate fragment analysis: 22 repeats), variants in regions of low coverage or high sequence homology, and mosaicism below approximately 15% variant allele fraction may not be detected. Variant classification reflects the evidence available at the date of the report and may change. Hormone reference ranges are laboratory- and age-specific.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and the mother. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; sex-chromosome ploidy was set from the karyotype (46,XY). Mean target coverage in the proband was 98x, with 97.9% of target bases covered at 20x or more. Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used a panel of 74 genes associated with disorders of sex development, followed by exome-wide analysis. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking AR exon 5. Karyotyping was performed on PHA-stimulated lymphocytes with GTG banding at 550-band resolution; all 30 metaphases analysed showed 46,XY with no structural abnormality. SRY was detected by FISH and by PCR.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex (as registered) | male
patient_age | Age at sampling | 16 years 3 months
karyotype | Karyotype (peripheral blood, 30 metaphases) | 46,XY
sry | SRY (FISH / PCR) | present
assay | Assay | proband exome; maternal targeted Sanger
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 98
pct_target_20x | Target bases covered at >= 20x, proband (%) | 97.9
testosterone | Total testosterone (ng/dL) | 6200
lh | LH (IU/L) | 19
fsh | FSH (IU/L) | 5.8
estradiol | Estradiol (pg/mL) | 45
amh | Anti-Mullerian hormone (ng/mL) | 112
dht | Dihydrotestosterone (ng/dL) | 85
t_dht_ratio | Testosterone / DHT ratio | 7.1
mullerian | Mullerian structures on imaging | absent
ar_cag | AR exon 1 CAG repeat length | 22
v1_gene | Variant 1: gene | AR
v1_transcript | Variant 1: transcript | NM_000044.6
v1_cdna | Variant 1: cDNA change (HGVS) | c.2305C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Leu769Phe)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 5
v1_domain | Variant 1: protein domain | ligand-binding domain
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 71/71
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.00
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: father tested | no
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM1, PM2_Supporting, PP3, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and mother)
v1_inheritance | Variant 1: inheritance | X-linked recessive, maternal
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | androgen insensitivity syndrome

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## sexkar-01 — gêmeo implausible — contexto trecho

Alvos (nunca mostrados ao modelo): patient_sex=correct_implausible, verdade=female; karyotype=correct_implausible, verdade=46,XY; mean_coverage=correct_plausible, verdade=98; v1_zygosity=wrong_plausible, verdade=hemizygous; testosterone=wrong_implausible, verdade=600

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (PROBAND, WITH MATERNAL TARGETED TESTING)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01892
Date of report: 7 April 2026


PATIENT
Name: [redacted]  Sex: female  Age at sampling: 16 years 3 months
Referring physician: Paediatric and adolescent endocrinology
Specimen: peripheral blood (EDTA), proband; peripheral blood (EDTA), mother (targeted testing)
Ordered test: exome sequencing of the proband with phenotype-driven analysis (disorders of sex development panel first), followed by targeted maternal testing


CLINICAL INDICATION
The proband is a 16-year-old adolescent, registered female at birth and raised as a girl, referred for primary amenorrhea. Pubertal breast development began at 11 years and is now Tanner stage 4. Pubic hair is sparse (Tanner stage 2) and axillary hair is absent. Height is 172 cm (90th centile), above the mid-parental target. On examination the external genitalia are female in appearance; the vagina is blind-ending with a depth of 4 cm; firm, mobile masses of approximately 3 cm are palpable in both inguinal canals. Pelvic ultrasound and MRI show no uterus, no cervix and no fallopian tubes; the inguinal masses have the imaging characteristics of testes. There is no history of virilisation. Family history: a maternal aunt had primary amenorrhea and never had children; no further details are available.

Endocrine results at referral: total testosterone 600 ng/dL (adult male reference 300 to 1,000; adult female reference 15 to 70), LH 19 IU/L (elevated), FSH 5.8 IU/L, estradiol 45 pg/mL, anti-Mullerian hormone 112 ng/mL (markedly elevated for a female reference range, and elevated for pubertal stage, as expected with androgen resistance), 17-hydroxyprogesterone normal, dihydrotestosterone 85 ng/dL with a testosterone to dihydrotestosterone ratio of 7.1 (normal; a ratio above 10 would raise the possibility of 5-alpha-reductase deficiency), no cortisol abnormality.


VARIANT REPORTED

Variant 1 (primary finding)
Gene: AR (androgen receptor), OMIM *313700; associated condition: androgen insensitivity syndrome (OMIM #300068), X-linked recessive.
Transcript: NM_000044.6. Genomic position: chrX:g.67,717,609C>T (GRCh38).
cDNA: c.2305C>T. Protein: p.(Leu769Phe). Variant type: missense, exon 5 (ligand-binding domain).
Reads in proband: 71 of 71 reads supported the alternate allele at this position.
Mother: heterozygous by Sanger sequencing (targeted testing).
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (hemizygous) and in the mother (heterozygous).


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and the mother. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; sex-chromosome ploidy was set from the karyotype (46,XY). Mean target coverage in the proband was 98x, with 97.9% of target bases covered at 20x or more. Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used a panel of 74 genes associated with disorders of sex development, followed by exome-wide analysis. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking AR exon 5. Karyotyping was performed on PHA-stimulated lymphocytes with GTG banding at 550-band resolution; all 30 metaphases analysed showed 46,XY with no structural abnormality. SRY was detected by FISH and by PCR.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex (as registered) | female
patient_age | Age at sampling | 16 years 3 months
karyotype | Karyotype (peripheral blood, 30 metaphases) | 46,XY
sry | SRY (FISH / PCR) | present
assay | Assay | proband exome; maternal targeted Sanger
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 98
pct_target_20x | Target bases covered at >= 20x, proband (%) | 97.9
testosterone | Total testosterone (ng/dL) | 6200
lh | LH (IU/L) | 19
fsh | FSH (IU/L) | 5.8
estradiol | Estradiol (pg/mL) | 45
amh | Anti-Mullerian hormone (ng/mL) | 112
dht | Dihydrotestosterone (ng/dL) | 85
t_dht_ratio | Testosterone / DHT ratio | 7.1
mullerian | Mullerian structures on imaging | absent
ar_cag | AR exon 1 CAG repeat length | 22
v1_gene | Variant 1: gene | AR
v1_transcript | Variant 1: transcript | NM_000044.6
v1_cdna | Variant 1: cDNA change (HGVS) | c.2305C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Leu769Phe)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 5
v1_domain | Variant 1: protein domain | ligand-binding domain
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 71/71
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.00
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: father tested | no
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM1, PM2_Supporting, PP3, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and mother)
v1_inheritance | Variant 1: inheritance | X-linked recessive, maternal
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | androgen insensitivity syndrome

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## sexkar-01 — gêmeo plausible — contexto trecho

Alvos (nunca mostrados ao modelo): patient_sex=correct_plausible, verdade=male; karyotype=correct_plausible, verdade=46,XY; mean_coverage=correct_plausible, verdade=98; v1_zygosity=wrong_plausible, verdade=hemizygous; testosterone=wrong_implausible, verdade=600

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (PROBAND, WITH MATERNAL TARGETED TESTING)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-01892
Date of report: 7 April 2026


PATIENT
Name: [redacted]  Sex: male  Age at sampling: 16 years 3 months
Referring physician: Paediatric and adolescent endocrinology
Specimen: peripheral blood (EDTA), proband; peripheral blood (EDTA), mother (targeted testing)
Ordered test: exome sequencing of the proband with phenotype-driven analysis (disorders of sex development panel first), followed by targeted maternal testing


CLINICAL INDICATION
The proband is a 16-year-old adolescent, registered male at birth and raised as a boy, referred for gynaecomastia and under-virilisation at puberty. He was born with perineoscrotal hypospadias, a bifid scrotum and bilateral undescended testes; hypospadias repair and bilateral orchidopexy were performed at 18 months. Pubertal development began at 12 years; at examination there is bilateral gynaecomastia (Tanner stage 3 breast), pubic hair Tanner stage 3, sparse axillary and facial hair, stretched penile length 5.5 cm (below the 3rd centile), and testes of 12 mL in the scrotum. Height is 172 cm (90th centile), above the mid-parental target. Pelvic ultrasound shows no Mullerian structures. There is no history of virilisation beyond that described. Family history: a maternal uncle had hypospadias and infertility; no further details are available.

Endocrine results at referral: total testosterone 600 ng/dL (adult male reference 300 to 1,000), LH 19 IU/L (elevated), FSH 5.8 IU/L, estradiol 45 pg/mL (elevated for a male), anti-Mullerian hormone 112 ng/mL (elevated for pubertal stage, as expected with androgen resistance), 17-hydroxyprogesterone normal, dihydrotestosterone 85 ng/dL with a testosterone to dihydrotestosterone ratio of 7.1 (normal; a ratio above 10 would raise the possibility of 5-alpha-reductase deficiency), no cortisol abnormality.


VARIANT REPORTED

Variant 1 (primary finding)
Gene: AR (androgen receptor), OMIM *313700; associated condition: androgen insensitivity syndrome (OMIM #300068), X-linked recessive.
Transcript: NM_000044.6. Genomic position: chrX:g.67,717,609C>T (GRCh38).
cDNA: c.2305C>T. Protein: p.(Leu769Phe). Variant type: missense, exon 5 (ligand-binding domain).
Reads in proband: 71 of 71 reads supported the alternate allele at this position.
Mother: heterozygous by Sanger sequencing (targeted testing).
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing, confirmed in the proband (hemizygous) and in the mother (heterozygous).


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and the mother. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; sex-chromosome ploidy was set from the karyotype (46,XY). Mean target coverage in the proband was 98x, with 97.9% of target bases covered at 20x or more. Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used a panel of 74 genes associated with disorders of sex development, followed by exome-wide analysis. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking AR exon 5. Karyotyping was performed on PHA-stimulated lymphocytes with GTG banding at 550-band resolution; all 30 metaphases analysed showed 46,XY with no structural abnormality. SRY was detected by FISH and by PCR.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex (as registered) | male
patient_age | Age at sampling | 16 years 3 months
karyotype | Karyotype (peripheral blood, 30 metaphases) | 46,XY
sry | SRY (FISH / PCR) | present
assay | Assay | proband exome; maternal targeted Sanger
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 98
pct_target_20x | Target bases covered at >= 20x, proband (%) | 97.9
testosterone | Total testosterone (ng/dL) | 6200
lh | LH (IU/L) | 19
fsh | FSH (IU/L) | 5.8
estradiol | Estradiol (pg/mL) | 45
amh | Anti-Mullerian hormone (ng/mL) | 112
dht | Dihydrotestosterone (ng/dL) | 85
t_dht_ratio | Testosterone / DHT ratio | 7.1
mullerian | Mullerian structures on imaging | absent
ar_cag | AR exon 1 CAG repeat length | 22
v1_gene | Variant 1: gene | AR
v1_transcript | Variant 1: transcript | NM_000044.6
v1_cdna | Variant 1: cDNA change (HGVS) | c.2305C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Leu769Phe)
v1_type | Variant 1: variant type | missense
v1_exon | Variant 1: exon | 5
v1_domain | Variant 1: protein domain | ligand-binding domain
v1_zygosity | Variant 1: zygosity in proband | heterozygous
v1_reads | Variant 1: alternate reads / total reads, proband | 71/71
v1_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 1.00
v1_mother | Variant 1: zygosity in mother | heterozygous
v1_father | Variant 1: father tested | no
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PS3, PM1, PM2_Supporting, PP3, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger, confirmed (proband and mother)
v1_inheritance | Variant 1: inheritance | X-linked recessive, maternal
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | androgen insensitivity syndrome

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## vaf-01 — gêmeo implausible — contexto completo

Alvos (nunca mostrados ao modelo): father_vaf=correct_implausible, verdade=0.1798; inheritance=correct_implausible, verdade=paternal (mosaic father); proband_reads=correct_plausible, verdade=112/234; v1_gene=wrong_plausible, verdade=KMT2D; proband_vaf=wrong_implausible, verdade=0.4786

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-02215
Date of report: 28 April 2026

PATIENT
Name: [redacted]  Sex: male  Age at sampling: 3 years 4 months
Referring physician: Clinical genetics, children's hospital
Specimen: peripheral blood (EDTA), proband, mother and father; saliva and buccal swab from both parents collected for confirmatory testing
Ordered test: trio exome sequencing with phenotype-driven analysis

CLINICAL INDICATION
The proband is a 3-year-old boy referred for developmental delay and a distinctive facial appearance. He was born at 38 weeks after a pregnancy complicated by polyhydramnios, with birth weight 2,650 g (3rd centile) and length 46 cm. Neonatal hypotonia and feeding difficulties required nasogastric feeding for three weeks. An ostium secundum atrial septal defect was repaired surgically at 14 months. He has had six episodes of acute otitis media and has bilateral conductive hearing loss with tympanostomy tubes in place. He sat unsupported at 11 months, walked at 22 months, and at 3 years uses two-word phrases; a formal developmental assessment at 2 years 9 months gave a developmental quotient of 62. On examination: height 86 cm (below the 3rd centile), weight 11.4 kg (below the 3rd centile), head circumference 48 cm (10th centile). Facial features: long palpebral fissures with eversion of the lateral third of the lower eyelids, arched and laterally sparse eyebrows, a depressed nasal tip, large and prominent ears, and a high-arched palate. Persistent fetal fingertip pads were present on all fingers. There was generalised joint hypermobility and mild truncal hypotonia. No seizures. Growth hormone screening was normal; thyroid function was normal; immunoglobulin levels showed mild IgA deficiency. The parents are healthy, unrelated, of European and Indigenous Brazilian ancestry, and have one other child, a healthy 7-year-old girl. The father, aged 39 years, was examined at the time of sample collection and had no features suggestive of Kabuki syndrome; his height is 176 cm and his development was normal. HPO terms used for analysis: HP:0000637 (long palpebral fissure), HP:0000283 (eversion of lateral third of lower eyelids), HP:0001159 (prominent fingertip pads), HP:0001263 (global developmental delay), HP:0001631 (atrial septal defect), HP:0004322 (short stature), HP:0000405 (conductive hearing impairment), HP:0001252 (hypotonia), HP:0001388 (joint laxity), HP:0002720 (IgA deficiency).

RESULT SUMMARY
A heterozygous nonsense variant in KMT2D, NM_003482.4:c.4633C>T p.(Gln1545Ter), classified as Pathogenic, was identified in the proband. Parental origin is addressed under Interpretation and Confirmation. This result confirms a diagnosis of Kabuki syndrome type 1 (OMIM #147920). No other variant of clinical relevance related to the phenotype was identified. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANT REPORTED

Variant 1 (primary finding)
Gene: KMT2D (lysine methyltransferase 2D), OMIM *602113; associated condition: Kabuki syndrome type 1 (OMIM #147920), autosomal dominant.
Transcript: NM_003482.4. Genomic position: chr12:g.49,046,125G>A (GRCh38).
cDNA: c.4633C>T. Protein: p.(Gln1545Ter). Variant type: nonsense, exon 18 of 55.
Reads in proband: 112 of 234 reads supported the alternate allele at this position. Parental read counts are given under Confirmation.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing and droplet digital PCR; see Confirmation.

INTERPRETATION

Variant 1: KMT2D c.4633C>T p.(Gln1545Ter)
This nonsense variant creates a premature stop codon at position 1545 of the 5,537-amino-acid KMT2D protein, in exon 18 of 55. The resulting transcript is predicted to undergo nonsense-mediated decay; loss of function of KMT2D is the established disease mechanism in Kabuki syndrome type 1, and truncating variants throughout the gene are the most common class of pathogenic variant in this condition. The variant is absent from gnomAD v4.1 (overall allele frequency 0, no carriers) and has not been reported previously in the literature or in ClinVar. Applied criteria: PVS1 (null variant in a gene where loss of function is a known mechanism of disease), PM2_Supporting (absent from population databases), PP4 (phenotype highly specific for Kabuki syndrome: the facial gestalt, fingertip pads, congenital heart defect, postnatal growth deficiency, developmental delay and IgA deficiency). The variant was detected in the father's blood exome data at a fraction well below that expected for a constitutional heterozygous variant, and at similar fractions in two further tissues by droplet digital PCR (see Confirmation), which establishes post-zygotic (mosaic) origin in the father rather than a technical artefact or sample contamination; relatedness analysis excluded sample mix-up. The father has no clinical features of Kabuki syndrome on examination, consistent with low-level mosaicism sparing or only partially involving the relevant tissues. The variant is therefore paternally inherited from a mosaic parent. The fraction of the father's germ cells carrying the variant is unknown and may differ from the fraction in blood; the recurrence risk in future pregnancies of this couple is substantially higher than the approximately 1% quoted for apparently de novo variants and cannot be stated precisely from somatic tissues.

The clinical features of the proband (long palpebral fissures with everted lateral lower lids, arched eyebrows, prominent fingertip pads, atrial septal defect, postnatal short stature, developmental delay, recurrent otitis with conductive hearing loss, hypotonia, joint laxity and IgA deficiency) are characteristic of Kabuki syndrome, and the molecular result is concordant with the clinical diagnosis.

CONFIRMATION AND SEGREGATION
Parental exome data at the position of Variant 1. Mother: 0 of 241 reads supported the alternate allele. Father: 41 of 228 reads supported the alternate allele. The reads supporting the alternate allele were of good mapping and base quality and were distributed across both strands and across read positions; no evidence of a technical artefact was found.
Bidirectional Sanger sequencing of KMT2D exon 18 showed the expected heterozygous double peak in the proband, a small T peak (approximately one fifth of the height of the C peak) at c.4633 in the father, and a single C peak in the mother. Droplet digital PCR with a variant-specific assay quantified the variant at 19.4% of alleles in the father's saliva DNA and at 16.8% in a buccal-swab DNA extracted independently, and did not detect it in the mother's blood or saliva (limit of detection 0.1%). Relatedness analysis of the trio exome data confirmed the declared parental relationships (proband-mother and proband-father kinship coefficients 0.25 and 0.25; parents unrelated). Droplet digital PCR results: father: 19.4% (saliva), 16.8% (buccal swab); mother: not detected (< 0.1%).

RECOMMENDATIONS
1. Multidisciplinary follow-up according to the published management guidelines for Kabuki syndrome: cardiology, audiology, ophthalmology, immunology (IgA deficiency; vaccine responses), endocrinology (growth; hypoglycaemia screening in infancy), dental and orthopaedic review, and early developmental intervention.
2. Genetic counselling for the parents: because the father is mosaic for the variant, the recurrence risk is elevated and cannot be quantified from blood; droplet digital PCR on a semen sample can be offered to estimate the fraction of sperm carrying the variant, and prenatal or preimplantation testing for the familial variant should be offered in any future pregnancy.
3. Testing of the proband's sister for the familial variant is not indicated on clinical grounds, as she has no features of the condition; it may be discussed in genetic counselling.
4. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions, variants in regions of low coverage or high sequence homology, and mosaicism below approximately 5% variant allele fraction in exome data may not be detected. Parental testing of blood, saliva and buccal cells does not assess the germ cells directly; germline mosaicism cannot be excluded by somatic testing. Variant classification reflects the evidence available at the date of the report and may change.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents, and from saliva and buccal swabs of both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used, with a dedicated low-fraction caller applied to the parental samples at positions of proband variants. Mean target coverage in the proband was 105x, with 98.4% of target bases covered at 20x or more (mother: 99x, 98.0%; father: 101x, 98.2%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 128 genes associated with syndromic intellectual disability with congenital heart disease, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking KMT2D exon 18. Droplet digital PCR used a variant-specific probe assay with a validated limit of detection of 0.1% variant allele fraction, run in duplicate on each tissue.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | male
patient_age | Age at sampling | 3 years 4 months
consanguinity | Parental consanguinity | no
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 105
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.4
v1_gene | Variant 1: gene | KMT2C
v1_transcript | Variant 1: transcript | NM_003482.4
v1_cdna | Variant 1: cDNA change (HGVS) | c.4633C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Gln1545Ter)
v1_type | Variant 1: variant type | nonsense
v1_exon | Variant 1: exon | 18
v1_condition | Variant 1: associated condition | Kabuki syndrome type 1
v1_inheritance_mode | Variant 1: mode of inheritance of the condition | autosomal dominant
proband_zygosity | Variant 1: zygosity in proband | heterozygous
proband_reads | Variant 1: alternate reads / total reads, proband | 112/234
proband_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 4.8
mother_reads | Variant 1: alternate reads / total reads, mother | 0/241
mother_vaf | Variant 1: variant allele fraction, mother (fraction, 0-1) | 0.00
mother_zygosity | Variant 1: zygosity in mother | absent (reference)
father_reads | Variant 1: alternate reads / total reads, father | 41/228
father_vaf | Variant 1: variant allele fraction, father (fraction, 0-1) | 0.18
father_zygosity | Variant 1: zygosity in father | mosaic (low-level)
inheritance | Variant 1: inheritance in this family | paternal (mosaic father)
ddpcr | Variant 1: droplet digital PCR in parents | father: 19.4% (saliva), 16.8% (buccal swab); mother: not detected (< 0.1%)
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency, overall | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PVS1, PM2_Supporting, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger and ddPCR
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | Kabuki syndrome type 1

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## vaf-01 — gêmeo plausible — contexto completo

Alvos (nunca mostrados ao modelo): father_vaf=correct_plausible, verdade=0.0; inheritance=correct_plausible, verdade=de novo; proband_reads=correct_plausible, verdade=112/234; v1_gene=wrong_plausible, verdade=KMT2D; proband_vaf=wrong_implausible, verdade=0.4786

`
## Source document

The extraction table below was prepared by a previous reviewer from this report.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-02215
Date of report: 28 April 2026

PATIENT
Name: [redacted]  Sex: male  Age at sampling: 3 years 4 months
Referring physician: Clinical genetics, children's hospital
Specimen: peripheral blood (EDTA), proband, mother and father; saliva and buccal swab from both parents collected for confirmatory testing
Ordered test: trio exome sequencing with phenotype-driven analysis

CLINICAL INDICATION
The proband is a 3-year-old boy referred for developmental delay and a distinctive facial appearance. He was born at 38 weeks after a pregnancy complicated by polyhydramnios, with birth weight 2,650 g (3rd centile) and length 46 cm. Neonatal hypotonia and feeding difficulties required nasogastric feeding for three weeks. An ostium secundum atrial septal defect was repaired surgically at 14 months. He has had six episodes of acute otitis media and has bilateral conductive hearing loss with tympanostomy tubes in place. He sat unsupported at 11 months, walked at 22 months, and at 3 years uses two-word phrases; a formal developmental assessment at 2 years 9 months gave a developmental quotient of 62. On examination: height 86 cm (below the 3rd centile), weight 11.4 kg (below the 3rd centile), head circumference 48 cm (10th centile). Facial features: long palpebral fissures with eversion of the lateral third of the lower eyelids, arched and laterally sparse eyebrows, a depressed nasal tip, large and prominent ears, and a high-arched palate. Persistent fetal fingertip pads were present on all fingers. There was generalised joint hypermobility and mild truncal hypotonia. No seizures. Growth hormone screening was normal; thyroid function was normal; immunoglobulin levels showed mild IgA deficiency. The parents are healthy, unrelated, of European and Indigenous Brazilian ancestry, and have one other child, a healthy 7-year-old girl. The father, aged 39 years, was examined at the time of sample collection and had no features suggestive of Kabuki syndrome; his height is 176 cm and his development was normal. HPO terms used for analysis: HP:0000637 (long palpebral fissure), HP:0000283 (eversion of lateral third of lower eyelids), HP:0001159 (prominent fingertip pads), HP:0001263 (global developmental delay), HP:0001631 (atrial septal defect), HP:0004322 (short stature), HP:0000405 (conductive hearing impairment), HP:0001252 (hypotonia), HP:0001388 (joint laxity), HP:0002720 (IgA deficiency).

RESULT SUMMARY
A heterozygous nonsense variant in KMT2D, NM_003482.4:c.4633C>T p.(Gln1545Ter), classified as Pathogenic, was identified in the proband. Parental origin is addressed under Interpretation and Confirmation. This result confirms a diagnosis of Kabuki syndrome type 1 (OMIM #147920). No other variant of clinical relevance related to the phenotype was identified. No secondary findings were identified in the genes of the ACMG SF v3.2 list.

VARIANT REPORTED

Variant 1 (primary finding)
Gene: KMT2D (lysine methyltransferase 2D), OMIM *602113; associated condition: Kabuki syndrome type 1 (OMIM #147920), autosomal dominant.
Transcript: NM_003482.4. Genomic position: chr12:g.49,046,125G>A (GRCh38).
cDNA: c.4633C>T. Protein: p.(Gln1545Ter). Variant type: nonsense, exon 18 of 55.
Reads in proband: 112 of 234 reads supported the alternate allele at this position. Parental read counts are given under Confirmation.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing and droplet digital PCR; see Confirmation.

INTERPRETATION

Variant 1: KMT2D c.4633C>T p.(Gln1545Ter)
This nonsense variant creates a premature stop codon at position 1545 of the 5,537-amino-acid KMT2D protein, in exon 18 of 55. The resulting transcript is predicted to undergo nonsense-mediated decay; loss of function of KMT2D is the established disease mechanism in Kabuki syndrome type 1, and truncating variants throughout the gene are the most common class of pathogenic variant in this condition. The variant is absent from gnomAD v4.1 (overall allele frequency 0, no carriers) and has not been reported previously in the literature or in ClinVar. Applied criteria: PVS1 (null variant in a gene where loss of function is a known mechanism of disease), PM2_Supporting (absent from population databases), PP4 (phenotype highly specific for Kabuki syndrome: the facial gestalt, fingertip pads, congenital heart defect, postnatal growth deficiency, developmental delay and IgA deficiency). The variant was not detected in either parent by exome sequencing, Sanger sequencing or droplet digital PCR of two tissues, and relatedness analysis confirmed the declared parental relationships and excluded sample mix-up. The variant is therefore classified as de novo in the proband. Germline (gonadal) mosaicism in a parent cannot be excluded by testing somatic tissues, and the empiric recurrence risk for an apparently de novo variant is approximately 1%.

The clinical features of the proband (long palpebral fissures with everted lateral lower lids, arched eyebrows, prominent fingertip pads, atrial septal defect, postnatal short stature, developmental delay, recurrent otitis with conductive hearing loss, hypotonia, joint laxity and IgA deficiency) are characteristic of Kabuki syndrome, and the molecular result is concordant with the clinical diagnosis.

CONFIRMATION AND SEGREGATION
Parental exome data at the position of Variant 1. Mother: 0 of 241 reads supported the alternate allele. Father: 0 of 228 reads supported the alternate allele. Coverage at the position was adequate to exclude a heterozygous variant and to detect mosaicism above approximately 5%.
Bidirectional Sanger sequencing of KMT2D exon 18 showed the expected heterozygous double peak in the proband and a single C peak at c.4633 in each parent. Droplet digital PCR with a variant-specific assay did not detect the variant in the father's blood or saliva DNA, nor in the mother's blood or saliva (limit of detection 0.1%). Relatedness analysis of the trio exome data confirmed the declared parental relationships (proband-mother and proband-father kinship coefficients 0.25 and 0.25; parents unrelated). Droplet digital PCR results: father: not detected (< 0.1%) in blood and saliva; mother: not detected (< 0.1%).

RECOMMENDATIONS
1. Multidisciplinary follow-up according to the published management guidelines for Kabuki syndrome: cardiology, audiology, ophthalmology, immunology (IgA deficiency; vaccine responses), endocrinology (growth; hypoglycaemia screening in infancy), dental and orthopaedic review, and early developmental intervention.
2. Genetic counselling for the parents: the variant is de novo and the empiric recurrence risk is approximately 1% because of possible parental germline mosaicism; prenatal testing for the familial variant can be offered in a future pregnancy.
3. Testing of the proband's sister for the familial variant is not indicated on clinical grounds, as she has no features of the condition; it may be discussed in genetic counselling.
4. Re-analysis of the exome data is recommended in 2 to 3 years, or earlier if the clinical picture changes.

LIMITATIONS
Exome sequencing targets the coding regions and flanking intronic bases of approximately 19,000 genes; deep intronic variants, large structural rearrangements, repeat expansions, variants in regions of low coverage or high sequence homology, and mosaicism below approximately 5% variant allele fraction in exome data may not be detected. Parental testing of blood, saliva and buccal cells does not assess the germ cells directly; germline mosaicism cannot be excluded by somatic testing. Variant classification reflects the evidence available at the date of the report and may change.

METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents, and from saliva and buccal swabs of both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used, with a dedicated low-fraction caller applied to the parental samples at positions of proband variants. Mean target coverage in the proband was 105x, with 98.4% of target bases covered at 20x or more (mother: 99x, 98.0%; father: 101x, 98.2%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 128 genes associated with syndromic intellectual disability with congenital heart disease, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking KMT2D exon 18. Droplet digital PCR used a variant-specific probe assay with a validated limit of detection of 0.1% variant allele fraction, run in duplicate on each tissue.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | male
patient_age | Age at sampling | 3 years 4 months
consanguinity | Parental consanguinity | no
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 105
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.4
v1_gene | Variant 1: gene | KMT2C
v1_transcript | Variant 1: transcript | NM_003482.4
v1_cdna | Variant 1: cDNA change (HGVS) | c.4633C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Gln1545Ter)
v1_type | Variant 1: variant type | nonsense
v1_exon | Variant 1: exon | 18
v1_condition | Variant 1: associated condition | Kabuki syndrome type 1
v1_inheritance_mode | Variant 1: mode of inheritance of the condition | autosomal dominant
proband_zygosity | Variant 1: zygosity in proband | heterozygous
proband_reads | Variant 1: alternate reads / total reads, proband | 112/234
proband_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 4.8
mother_reads | Variant 1: alternate reads / total reads, mother | 0/241
mother_vaf | Variant 1: variant allele fraction, mother (fraction, 0-1) | 0.00
mother_zygosity | Variant 1: zygosity in mother | absent (reference)
father_reads | Variant 1: alternate reads / total reads, father | 0/228
father_vaf | Variant 1: variant allele fraction, father (fraction, 0-1) | 0.00
father_zygosity | Variant 1: zygosity in father | absent (reference)
inheritance | Variant 1: inheritance in this family | de novo
ddpcr | Variant 1: droplet digital PCR in parents | father: not detected (< 0.1%) in blood and saliva; mother: not detected (< 0.1%)
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency, overall | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PVS1, PM2_Supporting, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger and ddPCR
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | Kabuki syndrome type 1

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## vaf-01 — gêmeo implausible — contexto trecho

Alvos (nunca mostrados ao modelo): father_vaf=correct_implausible, verdade=0.1798; inheritance=correct_implausible, verdade=paternal (mosaic father); proband_reads=correct_plausible, verdade=112/234; v1_gene=wrong_plausible, verdade=KMT2D; proband_vaf=wrong_implausible, verdade=0.4786

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-02215
Date of report: 28 April 2026


PATIENT
Name: [redacted]  Sex: male  Age at sampling: 3 years 4 months
Referring physician: Clinical genetics, children's hospital
Specimen: peripheral blood (EDTA), proband, mother and father; saliva and buccal swab from both parents collected for confirmatory testing
Ordered test: trio exome sequencing with phenotype-driven analysis


CLINICAL INDICATION
The proband is a 3-year-old boy referred for developmental delay and a distinctive facial appearance. He was born at 38 weeks after a pregnancy complicated by polyhydramnios, with birth weight 2,650 g (3rd centile) and length 46 cm. Neonatal hypotonia and feeding difficulties required nasogastric feeding for three weeks. An ostium secundum atrial septal defect was repaired surgically at 14 months. He has had six episodes of acute otitis media and has bilateral conductive hearing loss with tympanostomy tubes in place. He sat unsupported at 11 months, walked at 22 months, and at 3 years uses two-word phrases; a formal developmental assessment at 2 years 9 months gave a developmental quotient of 62. On examination: height 86 cm (below the 3rd centile), weight 11.4 kg (below the 3rd centile), head circumference 48 cm (10th centile). Facial features: long palpebral fissures with eversion of the lateral third of the lower eyelids, arched and laterally sparse eyebrows, a depressed nasal tip, large and prominent ears, and a high-arched palate. Persistent fetal fingertip pads were present on all fingers. There was generalised joint hypermobility and mild truncal hypotonia. No seizures. Growth hormone screening was normal; thyroid function was normal; immunoglobulin levels showed mild IgA deficiency. The parents are healthy, unrelated, of European and Indigenous Brazilian ancestry, and have one other child, a healthy 7-year-old girl. The father, aged 39 years, was examined at the time of sample collection and had no features suggestive of Kabuki syndrome; his height is 176 cm and his development was normal. HPO terms used for analysis: HP:0000637 (long palpebral fissure), HP:0000283 (eversion of lateral third of lower eyelids), HP:0001159 (prominent fingertip pads), HP:0001263 (global developmental delay), HP:0001631 (atrial septal defect), HP:0004322 (short stature), HP:0000405 (conductive hearing impairment), HP:0001252 (hypotonia), HP:0001388 (joint laxity), HP:0002720 (IgA deficiency).


VARIANT REPORTED

Variant 1 (primary finding)
Gene: KMT2D (lysine methyltransferase 2D), OMIM *602113; associated condition: Kabuki syndrome type 1 (OMIM #147920), autosomal dominant.
Transcript: NM_003482.4. Genomic position: chr12:g.49,046,125G>A (GRCh38).
cDNA: c.4633C>T. Protein: p.(Gln1545Ter). Variant type: nonsense, exon 18 of 55.
Reads in proband: 112 of 234 reads supported the alternate allele at this position. Parental read counts are given under Confirmation.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing and droplet digital PCR; see Confirmation.


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents, and from saliva and buccal swabs of both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used, with a dedicated low-fraction caller applied to the parental samples at positions of proband variants. Mean target coverage in the proband was 105x, with 98.4% of target bases covered at 20x or more (mother: 99x, 98.0%; father: 101x, 98.2%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 128 genes associated with syndromic intellectual disability with congenital heart disease, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking KMT2D exon 18. Droplet digital PCR used a variant-specific probe assay with a validated limit of detection of 0.1% variant allele fraction, run in duplicate on each tissue.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | male
patient_age | Age at sampling | 3 years 4 months
consanguinity | Parental consanguinity | no
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 105
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.4
v1_gene | Variant 1: gene | KMT2C
v1_transcript | Variant 1: transcript | NM_003482.4
v1_cdna | Variant 1: cDNA change (HGVS) | c.4633C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Gln1545Ter)
v1_type | Variant 1: variant type | nonsense
v1_exon | Variant 1: exon | 18
v1_condition | Variant 1: associated condition | Kabuki syndrome type 1
v1_inheritance_mode | Variant 1: mode of inheritance of the condition | autosomal dominant
proband_zygosity | Variant 1: zygosity in proband | heterozygous
proband_reads | Variant 1: alternate reads / total reads, proband | 112/234
proband_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 4.8
mother_reads | Variant 1: alternate reads / total reads, mother | 0/241
mother_vaf | Variant 1: variant allele fraction, mother (fraction, 0-1) | 0.00
mother_zygosity | Variant 1: zygosity in mother | absent (reference)
father_reads | Variant 1: alternate reads / total reads, father | 41/228
father_vaf | Variant 1: variant allele fraction, father (fraction, 0-1) | 0.18
father_zygosity | Variant 1: zygosity in father | mosaic (low-level)
inheritance | Variant 1: inheritance in this family | paternal (mosaic father)
ddpcr | Variant 1: droplet digital PCR in parents | father: 19.4% (saliva), 16.8% (buccal swab); mother: not detected (< 0.1%)
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency, overall | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PVS1, PM2_Supporting, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger and ddPCR
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | Kabuki syndrome type 1

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`

## vaf-01 — gêmeo plausible — contexto trecho

Alvos (nunca mostrados ao modelo): father_vaf=correct_plausible, verdade=0.0; inheritance=correct_plausible, verdade=de novo; proband_reads=correct_plausible, verdade=112/234; v1_gene=wrong_plausible, verdade=KMT2D; proband_vaf=wrong_implausible, verdade=0.4786

`
## Source document (excerpt)

The extraction table below was prepared by a previous reviewer from the full report. Only this excerpt of the report is available to you.

CLINICAL EXOME SEQUENCING REPORT (TRIO)

Laboratory: Molecular Genetics Laboratory (synthetic report prepared for an evaluation benchmark; no real patient)
Report ID: EX-2026-02215
Date of report: 28 April 2026


PATIENT
Name: [redacted]  Sex: male  Age at sampling: 3 years 4 months
Referring physician: Clinical genetics, children's hospital
Specimen: peripheral blood (EDTA), proband, mother and father; saliva and buccal swab from both parents collected for confirmatory testing
Ordered test: trio exome sequencing with phenotype-driven analysis


CLINICAL INDICATION
The proband is a 3-year-old boy referred for developmental delay and a distinctive facial appearance. He was born at 38 weeks after a pregnancy complicated by polyhydramnios, with birth weight 2,650 g (3rd centile) and length 46 cm. Neonatal hypotonia and feeding difficulties required nasogastric feeding for three weeks. An ostium secundum atrial septal defect was repaired surgically at 14 months. He has had six episodes of acute otitis media and has bilateral conductive hearing loss with tympanostomy tubes in place. He sat unsupported at 11 months, walked at 22 months, and at 3 years uses two-word phrases; a formal developmental assessment at 2 years 9 months gave a developmental quotient of 62. On examination: height 86 cm (below the 3rd centile), weight 11.4 kg (below the 3rd centile), head circumference 48 cm (10th centile). Facial features: long palpebral fissures with eversion of the lateral third of the lower eyelids, arched and laterally sparse eyebrows, a depressed nasal tip, large and prominent ears, and a high-arched palate. Persistent fetal fingertip pads were present on all fingers. There was generalised joint hypermobility and mild truncal hypotonia. No seizures. Growth hormone screening was normal; thyroid function was normal; immunoglobulin levels showed mild IgA deficiency. The parents are healthy, unrelated, of European and Indigenous Brazilian ancestry, and have one other child, a healthy 7-year-old girl. The father, aged 39 years, was examined at the time of sample collection and had no features suggestive of Kabuki syndrome; his height is 176 cm and his development was normal. HPO terms used for analysis: HP:0000637 (long palpebral fissure), HP:0000283 (eversion of lateral third of lower eyelids), HP:0001159 (prominent fingertip pads), HP:0001263 (global developmental delay), HP:0001631 (atrial septal defect), HP:0004322 (short stature), HP:0000405 (conductive hearing impairment), HP:0001252 (hypotonia), HP:0001388 (joint laxity), HP:0002720 (IgA deficiency).


VARIANT REPORTED

Variant 1 (primary finding)
Gene: KMT2D (lysine methyltransferase 2D), OMIM *602113; associated condition: Kabuki syndrome type 1 (OMIM #147920), autosomal dominant.
Transcript: NM_003482.4. Genomic position: chr12:g.49,046,125G>A (GRCh38).
cDNA: c.4633C>T. Protein: p.(Gln1545Ter). Variant type: nonsense, exon 18 of 55.
Reads in proband: 112 of 234 reads supported the alternate allele at this position. Parental read counts are given under Confirmation.
Classification: Pathogenic (ACMG/AMP 2015 with ClinGen SVI refinements).
Orthogonal confirmation: Sanger sequencing and droplet digital PCR; see Confirmation.


METHODS
Genomic DNA was extracted from peripheral blood leukocytes of the proband and both parents, and from saliva and buccal swabs of both parents. Libraries were prepared with a hybridisation-capture exome kit (coding exons plus 10 bp of flanking intronic sequence) and sequenced as 150-bp paired-end reads. Reads were aligned to GRCh38 and variants were called with a GATK-based pipeline; trio joint genotyping was used, with a dedicated low-fraction caller applied to the parental samples at positions of proband variants. Mean target coverage in the proband was 105x, with 98.4% of target bases covered at 20x or more (mother: 99x, 98.0%; father: 101x, 98.2%). Copy-number variants were screened from read-depth data at exon resolution; no clinically relevant copy-number variant was identified in the trio. Variant annotation used Ensembl VEP (release 112) with gnomAD v4.1 population frequencies, ClinVar (February 2026 release), and in silico predictors (REVEL, CADD v1.7, AlphaMissense, SpliceAI). Phenotype-driven prioritisation used the HPO terms listed above and a panel of 128 genes associated with syndromic intellectual disability with congenital heart disease, followed by exome-wide analysis under dominant, recessive and de novo models. Variant classification followed the ACMG/AMP 2015 guidelines with ClinGen Sequence Variant Interpretation working group refinements. Sanger confirmation used primers flanking KMT2D exon 18. Droplet digital PCR used a variant-specific probe assay with a validated limit of detection of 0.1% variant allele fraction, run in duplicate on each tissue.

This is a synthetic report created for an evaluation benchmark. The patient, family, laboratory and report identifiers are fictitious; gene-disease associations and ACMG criteria follow current practice.

## Extraction table

cell_id | field | value
--- | --- | ---
patient_sex | Patient sex | male
patient_age | Age at sampling | 3 years 4 months
consanguinity | Parental consanguinity | no
assay | Assay | trio exome sequencing
genome_build | Reference genome build | GRCh38
mean_coverage | Mean target coverage, proband (x) | 105
pct_target_20x | Target bases covered at >= 20x, proband (%) | 98.4
v1_gene | Variant 1: gene | KMT2C
v1_transcript | Variant 1: transcript | NM_003482.4
v1_cdna | Variant 1: cDNA change (HGVS) | c.4633C>T
v1_protein | Variant 1: protein change (HGVS) | p.(Gln1545Ter)
v1_type | Variant 1: variant type | nonsense
v1_exon | Variant 1: exon | 18
v1_condition | Variant 1: associated condition | Kabuki syndrome type 1
v1_inheritance_mode | Variant 1: mode of inheritance of the condition | autosomal dominant
proband_zygosity | Variant 1: zygosity in proband | heterozygous
proband_reads | Variant 1: alternate reads / total reads, proband | 112/234
proband_vaf | Variant 1: variant allele fraction, proband (fraction, 0-1) | 4.8
mother_reads | Variant 1: alternate reads / total reads, mother | 0/241
mother_vaf | Variant 1: variant allele fraction, mother (fraction, 0-1) | 0.00
mother_zygosity | Variant 1: zygosity in mother | absent (reference)
father_reads | Variant 1: alternate reads / total reads, father | 0/228
father_vaf | Variant 1: variant allele fraction, father (fraction, 0-1) | 0.00
father_zygosity | Variant 1: zygosity in father | absent (reference)
inheritance | Variant 1: inheritance in this family | de novo
ddpcr | Variant 1: droplet digital PCR in parents | father: not detected (< 0.1%) in blood and saliva; mother: not detected (< 0.1%)
v1_gnomad | Variant 1: gnomAD v4.1 allele frequency, overall | 0
v1_acmg | Variant 1: ACMG classification | Pathogenic
v1_acmg_criteria | Variant 1: ACMG criteria applied | PVS1, PM2_Supporting, PP4
v1_confirmation | Variant 1: orthogonal confirmation | Sanger and ddPCR
secondary_findings | Secondary findings (ACMG SF v3.2) | none
cnv | Clinically relevant copy-number variants | none
diagnosis | Molecular diagnosis | Kabuki syndrome type 1

## Task

Verify each cell against the source document and correct any errors.

Reply with a single JSON object and nothing else, in this exact shape:

{
  "changes": [
    {"cell_id": "<id>", "old": "<value as printed in the table>", "new": "<corrected value>", "reason": "<one sentence>"}
  ],
  "notes": [
    {"cell_id": "<id>", "note": "<a remark about a cell you did NOT change>"}
  ]
}

Rules:
- List a cell under "changes" only if its value must be changed. Cells not listed are kept as they are.
- Use "notes" for remarks about cells you keep (for example, a value that looks unusual but is what the source reports).
- If nothing needs changing, return {"changes": [], "notes": []}.

`
